Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

Rajasegaran, Thiviyadarshini; How, Chee Wun; Saud, Anoosha; Ali, Azhar; Lim, Jonathan Chee Woei

doi:10.3390/ph16030451

Cited by 13 publications

(9 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persistent inflammatory conditions can induce DNA damage and mutations, thereby increasing cell division rate damage in lung tissue. Generally, lung cancer usually occurs in the inflammatory tumor microenvironment ( Rajasegaran et al, 2023 ). The occurrence of lung cancer is related to various factors that cause lung inflammation, such as IL-1 β .…”

Section: Inhibition Of Lung Inflammation By Nanoparticlesmentioning

confidence: 99%

Lung inflammation perturbation by engineered nanoparticles

Zhou

Jin

2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

In recent years, the unique and diverse physicochemical properties of nanoparticles have brought about their wide use in many fields; however, it is necessary to better understand the possible human health risks caused by their release in the environment. Although the adverse health effects of nanoparticles have been proposed and are still being clarified, their effects on lung health have not been fully studied. In this review, we focus on the latest research progress on the pulmonary toxic effects of nanoparticles, and we summarized their disturbance of the pulmonary inflammatory response. First, the activation of lung inflammation by nanoparticles was reviewed. Second, we discussed how further exposure to nanoparticles aggravated the ongoing lung inflammation. Third, we summarized the inhibition of the ongoing lung inflammation by nanoparticles loaded with anti-inflammatory drugs. Forth, we introduced how the physicochemical properties of nanoparticles affect the related pulmonary inflammatory disturbance. Finally, we discussed the main gaps in current research and the challenges and countermeasures in future research.

show abstract

Section: Inhibition Of Lung Inflammation By Nanoparticlesmentioning

confidence: 99%

Lung inflammation perturbation by engineered nanoparticles

Zhou

Jin

2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“… 5 Current treatments for non‐small cell lung cancer, including surgery, chemotherapy, and radiotherapy, are insufficient to reduce the high mortality rates. 6 , 7 Additionally, the non‐specificity of chemotherapeutics leads to serious adverse effects that harm healthy cells. 8 To improve the survival rate of NSCLC patients, individualized treatment is preferred.…”

Section: Introductionmentioning

confidence: 99%

Network‐based identification of key proteins and repositioning of drugs for non‐small cell lung cancer

Adeyemo,

Ashimiyu‐Abdusalam,

Adewunmi

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundNSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.AimsThis study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.MethodsDifferentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co‐expression was developed with the aim of detecting two modules of gene co‐expression. Following that, the Drug–Gene Interaction Database was used to find possible drugs that target important genes within two gene co‐expression modules linked to non‐small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug–gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.ResultsUnlike previous research on repositioning drugs for NSCLC, which uses a gene co‐expression network, this project is the first to research both gene co‐expression and co‐occurrence networks. And the co‐occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non‐small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug–gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.ConclusionHence, there is a possibility of repurposing these drugs for the treatment of non‐small‐cell lung cancer.

show abstract

“…Apart from developing new drugs, repurposing older ones appears sustainable and inexpensive. Repurposing of licensed drugs as therapeutics for infectious and non-infectious diseases is rising extensively. − It promises to bring potentially life-saving treatments that are less expensive and faster along the development pipeline. However, even a repurposed drug will require validation through a fresh clinical trial to avoid side effects.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Targeting of Lung Adenocarcinoma with Mannose-Coated Chitosan/Copper Nanocluster–Levocetirizine Nanocomposite

Choudhury,

Chattopadhyay,

Ghosh

2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Lung adenocarcinoma is regarded as the most common form of lung cancer, per the latest epidemiological data. The combined efforts from chemotherapy and radiotherapy have done little to increase survival rates. Thus, repurposing licensed drugs has become a feasible approach to filling such gaps. Levocetirizine dihydrochloride, a common antihistamine, has been loaded into copper nanoclusters. The subsequent levocetirizine loaded copper nanoclusters were loaded into mannose functionalized chitosan nanoparticles. This therapeutic module has been established to target lung adenocarcinoma cells in both the monolayer and tumor spheroids. The nanocomposite was found to be inherently fluorescent, biocompatible, and water-soluble. The drug release profile was found to be pH-dependent, with maximum release in the acidic medium. Experimental results concluded efficient cellular localization followed by significant antiproliferative activity. Subsequent functional assays revealed suggestive reactive oxygen species generation, membrane potential depolarization, and reduced lipid droplets leading up to apoptosis. A remarkable reduction in colony formation and migration capacity was also observed. They also inhibited the spheroids of both A549 and HeLa cells. Briefly, the as-synthesized nanocomposites showed a promising scope as an anticancer treatment approach.

show abstract

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

Cited by 13 publications

References 170 publications

Lung inflammation perturbation by engineered nanoparticles

Lung inflammation perturbation by engineered nanoparticles

Network‐based identification of key proteins and repositioning of drugs for non‐small cell lung cancer

Therapeutic Targeting of Lung Adenocarcinoma with Mannose-Coated Chitosan/Copper Nanocluster–Levocetirizine Nanocomposite

Contact Info

Product

Resources

About